---
title: Procter & Gamble (PG) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/pg
ticker: PG
as_of: 2026-10-17
sector: Consumer Defensive
industry: Household & Personal Products
---
# Procter & Gamble (PG)

Procter & Gamble (PG) closed at $159.31 on Oct 16, 2026, overvalued by 32% vs its model value of $120.99 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $159.31 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $120.99 |
| Price vs model | overvalued by 32% vs model |
| Range of that model | $73.70 – $333.35 |
| Market value | $370.0B |
| P/E (fiscal 2026) | 24.1 |
| Net margin (fiscal 2026) | 18.4% |
| Free cash flow (fiscal 2026) | $15.1B |
| Dividend yield (trailing twelve months) | 2.69% |
| Beta | 0.38 |
| Cost of capital (WACC) | 7.21% |
| Business classification | Dividend Payer (Low/slowing growth (~2% recent), Moderate margins (18% net margin), Pays dividends, Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Largest companies | #29 | $370.0B | https://sweetvaluelab.com/lists/largest-companies |
| Dividend growth streaks | #12 | 42 years | https://sweetvaluelab.com/lists/dividend-growth-streaks |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 2.69% |
| Dividends per share, last 12 months | $4.29 |
| Dividends / free cash flow (fiscal 2026) | 67.6% |
| Raised | 42 years in a row |
| Growth over 5 years | 5.3% a year |
| Latest payment | $1.0885, ex-date Jul 24, 2026, paid Aug 17, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Jul 22, 2021 | $3.32 |
| To Jul 21, 2022 | $3.57 |
| To Jul 20, 2023 | $3.71 |
| To Jul 19, 2024 | $3.89 |
| To Jul 18, 2025 | $4.13 |
| Trailing twelve months (to Jul 24, 2026) | $4.29 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $120.99 | $73.70 | $333.35 |
| DCF · Perpetuity growth · 10y | cross check | $124.10 | $78.17 | $326.95 |
| DCF · EBITDA exit · 5y | cross check | $133.94 | $95.41 | $179.35 |
| DCF · EBITDA exit · 10y | cross check | $134.98 | $94.54 | $188.86 |
| P/E · peers | cross check | $164.56 | $103.67 | $211.24 |
| P/E · own history | cross check | $175.39 | $161.76 | $187.28 |
| PEG | sanity check | $55.78 | $55.78 | $55.78 |
| EV/EBITDA · peers | cross check | $162.58 | $131.69 | $212.50 |
| EV/Revenue · peers | cross check | $91.59 | $69.55 | $143.53 |
| Earnings power value | cross check | $59.86 | $47.83 | $78.21 |
| Dividend discount | cross check | $91.23 | $59.72 | $166.71 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 3 open-market sales ($1.2M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 13, 2026 | Subramaniam Rajesh | Director | Grant / award | 1,438 | $0 |
| Oct 13, 2026 | Portman Robert Jones | Director | Grant / award | 1,438 | $0 |
| Oct 13, 2026 | McEvoy Ashley | Director | Grant / award | 1,438 | $0 |
| Oct 13, 2026 | McCarthy Christine M | Director | Grant / award | 1,438 | $0 |
| Oct 13, 2026 | Kempczinski Christopher J | Director | Grant / award | 1,438 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 16, 2026 | 8-K | 5.07 Submission of Matters to a Shareholder Vote | https://www.sec.gov/Archives/edgar/data/80424/000008042426000245/pg-20261016.htm |
| Oct 15, 2026 | S-3ASR | Shelf registration (automatic) | https://www.sec.gov/Archives/edgar/data/80424/000008042426000243/proctergambledss-3asr.htm |
| Oct 15, 2026 | S-3ASR | Shelf registration (automatic) | https://www.sec.gov/Archives/edgar/data/80424/000008042426000241/proctergambledsppforms-3asr.htm |
| Oct 15, 2026 | S-3ASR | Shelf registration (automatic) | https://www.sec.gov/Archives/edgar/data/80424/000008042426000239/proctergambleuksiss-3asr.htm |
| Oct 13, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/80424/000008042426000214/pg-20261013.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Terry Smith | 2026-06-30 | 4,078,371 | $598.1M |
| Yacktman | 2026-06-30 | 1,963,488 | $287.9M |
| Jensen | 2026-06-30 | 860,442 | $126.2M |
| Mairs & Power | 2026-06-30 | 245,423 | $36.0M |

10 tracked managers in all.

## About

The Procter & Gamble Company, commonly referred to as P&G, is a global enterprise that supplies a broad spectrum of branded consumer products to markets worldwide. The company's operations are divided into five main business divisions: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers an assortment of hair care products, including conditioners, shampoos, styling aids, and treatments, under popular names like Head & Shoulders, Herbal Essences, Pantene, and Rejoice. It also features antiperspirants, deodorants, personal cleansing solutions, and skin care items from brands such as Olay, Old Spice, Safeguard, Secret, and SK-II. Within the Grooming division, P&G provides a range of shave care products and grooming appliances, prominently featuring brands like Braun, Gillette, and Venus. The Health Care unit encompasses oral hygiene…

---

Source: https://sweetvaluelab.com/stocks/pg (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.